Outlook Therapeutics (OTLK) Current Deferred Revenue (2015 - 2019)

Outlook Therapeutics (OTLK) has 5 years of Current Deferred Revenue data on file, last reported at $2.3 million in Q2 2019.

• Current Deferred Revenue for Q2 2019 came in at $2.3 million, up 5.8% year-over-year; the trailing twelve-month figure through Jun 2019 was $2.3 million (up 5.8% YoY), and the FY2018 annual result was $1.7 million, down 43.69% from the prior year.
• Current Deferred Revenue steadied at $2.3 million in Q2 2019 per OTLK's latest filing, from $2.3 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $3.1 million in Q3 2017 and troughed at $1.2 million in Q3 2016.
• A 5-year average of $2.0 million and a median of $2.0 million in 2015 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2017 and 2018: Current Deferred Revenue soared 154.63% in 2017, then plunged 43.69% in 2018.
• A 5-year view of Current Deferred Revenue shows it stood at $2.0 million in 2015, then slumped by 38.75% to $1.2 million in 2016, then soared by 126.82% to $2.8 million in 2017, then decreased by 13.0% to $2.4 million in 2018, then dropped by 2.39% to $2.3 million in 2019.
• Business Quant data shows OTLK's Current Deferred Revenue at $2.3 million in Q2 2019, $2.3 million in Q1 2019, and $2.4 million in Q4 2018.